Download MendeleyX-ray crystallographic and kinetic studies of biguanide containing aryl sulfonamides as carbonic anhydrase inhibitors.
Baroni, C., Bozdag, M., Renzi, G., De Luca, V., Capasso, C., Bazzicalupi, C., Selleri, S., Ferraroni, M., Carta, F., Supuran, C.T.(2025) RSC Med Chem 16: 1633-1640
- PubMed: 39935522 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1039/d4md01018c
- Primary Citation Related Structures:
8RNS, 8ROU, 8ROW, 9H0V - PubMed Abstract:
Here, we report a small series of dual-targeting compounds that combine the prototypical carbonic anhydrase (CA) zinc-binding sulfonamide moiety with the biguanide group of metformin, an emerging anticancer drug. The compounds reported similar in vitro inhibition profiles on a panel of physiologically relevant human (h)CAs, with marked selectivity for the cancer related IX and XII isoforms. The binding modes of representative inhibitors 5b and 5c within the active site of the hCA isoforms II and XII-mimic were assessed by X-ray crystallography, thus allowing us to clarify molecular features that may be useful for the design of more specific and potent inhibitors. For instance, we identified a mutation in the hCA XII-mimic which was found responsible for the selectivity of the ligands toward the tumor associated isoform. Interestingly, in the hCA II/5c complex, a second inhibitor molecule was bound to the catalytic cleft, probably affecting the inhibition properties of the canonical zinc-bound inhibitor.
- Department of Chemistry "Ugo Schiff", University of Florence Via della Lastruccia 3 50019 Sesto Fiorentino FI Italy marta.ferraroni@unifi.it.
Organizational Affiliation:
